These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 34595175)

  • 41. Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review.
    Li J; Wang X; Li N; Jiang Y; Huang H; Wang T; Lin Z; Xiong N
    Curr Gene Ther; 2020; 20(4):285-288. PubMed ID: 32867652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current Clinical Application of Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients: Review.
    Adugna DG
    Stem Cells Cloning; 2021; 14():71-80. PubMed ID: 34785907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs.
    Jamshidi E; Babajani A; Soltani P; Niknejad H
    Stem Cell Rev Rep; 2021 Feb; 17(1):176-192. PubMed ID: 33432484
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of MSC in Patients with Severe COVID-19: Analysis of the Literature and a Case Study.
    Grumet M; Sherman J; Dorf BS
    Stem Cells Transl Med; 2022 Nov; 11(11):1103-1112. PubMed ID: 36181766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mesenchymal stem cell therapy for COVID-19.
    Sengul F; Ozturk B; Vatansev H
    Am J Stem Cells; 2021; 10(5):79-89. PubMed ID: 35103115
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epigenetic modifications associated with genes implicated in cytokine storm: The potential biotherapeutic effects of vitamins and minerals in COVID-19.
    Muhammad A; Forcados GE; Sani H; Ndidi US; Adamu A; Katsayal BS; Sadiq IZ; Abubakar YS; Sulaiman I; Abubakar IB; Yusuf AP; Malami I; Ibrahim S; Abubakar MB
    J Food Biochem; 2022 May; 46(5):e14079. PubMed ID: 35060145
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Direct comparison of different therapeutic cell types susceptibility to inflammatory cytokines associated with COVID-19 acute lung injury.
    Vaka R; Khan S; Ye B; Risha Y; Parent S; Courtman D; Stewart DJ; Davis DR
    Stem Cell Res Ther; 2022 Jan; 13(1):20. PubMed ID: 35033181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm.
    Chau AS; Weber AG; Maria NI; Narain S; Liu A; Hajizadeh N; Malhotra P; Bloom O; Marder G; Kaplan B
    Arthritis Rheumatol; 2021 Jan; 73(1):23-35. PubMed ID: 32929876
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective.
    Gupta A; Kashte S; Gupta M; Rodriguez HC; Gautam SS; Kadam S
    Hum Cell; 2020 Oct; 33(4):907-918. PubMed ID: 32780299
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Implications of Low-grade Inflammation in SARS-CoV-2 Immunopathology.
    Suárez-Reyes A; Villegas-Valverde CA
    MEDICC Rev; 2021 Apr; 23(2):42. PubMed ID: 33974614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study.
    Dauletova M; Hafsan H; Mahhengam N; Zekiy AO; Ahmadi M; Siahmansouri H
    Clin Immunol; 2021 May; 226():108712. PubMed ID: 33684527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy.
    Li YE; Ajoolabady A; Dhanasekaran M; Ren J
    Pharmacol Res; 2022 Aug; 182():106334. PubMed ID: 35779816
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can
    Choi JH; Lee YH; Kwon TW; Ko SG; Nah SY; Cho IH
    J Ginseng Res; 2022 May; 46(3):337-347. PubMed ID: 35233163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transplantation of Mesenchymal Stem Cells: A Potential Adjuvant Therapy for COVID-19.
    Zhu Y; Geng S; Li Q; Jiang H
    Front Bioeng Biotechnol; 2020; 8():557652. PubMed ID: 33224928
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Research Progress of Mesenchymal Stem Cell Therapy for Severe COVID-19.
    Cai Q; Yin F; Hao L; Jiang W
    Stem Cells Dev; 2021 May; 30(9):459-472. PubMed ID: 33715385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.
    Song N; Wakimoto H; Rossignoli F; Bhere D; Ciccocioppo R; Chen KS; Khalsa JK; Mastrolia I; Samarelli AV; Dominici M; Shah K
    Stem Cells; 2021 Jun; 39(6):707-722. PubMed ID: 33586320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of mesenchymal stem cells in COVID-19 treatment.
    Yıldız Gülhan P
    Tuberk Toraks; 2020 Dec; 68(4):430-436. PubMed ID: 33448740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunosenescence and inflamm-ageing in COVID-19.
    Zinatizadeh MR; Zarandi PK; Ghiasi M; Kooshki H; Mohammadi M; Amani J; Rezaei N
    Ageing Res Rev; 2023 Feb; 84():101818. PubMed ID: 36516928
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID-19: imbalanced cell-mediated immune response drives to immunopathology.
    Wang J; Li Q; Qiu Y; Lu H
    Emerg Microbes Infect; 2022 Dec; 11(1):2393-2404. PubMed ID: 36069182
    [TBL] [Abstract][Full Text] [Related]  

  • 60. COVID-19 and HIV-Associated Immune Reconstitution Inflammatory Syndrome: Emergence of Pathogen-Specific Immune Responses Adding Fuel to the Fire.
    Seddiki N; French M
    Front Immunol; 2021; 12():649567. PubMed ID: 33841434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.